6-Mono- and 6,6-disubstituted 3-r-6,7-dihydro-2h-[1,2,4]-triazino[2,3-c]quinazoline-2-ones – promising class of anticancer agents


  • O. Yu. Voskoboynik Zaporizhzhia State Medical University
  • I. S. Nosulenko Zaporizhzhia State Medical University
  • G. G. Berest Zaporizhzhia State Medical University
  • S. I. Kovalenko Zaporizhzhia State Medical University




6-mono- і 6, 6-disubstituted 3-R-6, 7-dihydro-2H-[1, 2, 4]triazino[2, 3-c]quinazoline-2-ones, in vitro screening, anticancer activity


Anticancer activity of novel 6-mono- and 6,6-disubstituted  3-R-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]quinazolin-2-ones was described in presented manuscript. It was shown, that 10-bromo-6-isobutyl-3-(4-fluorophenyl)-6,7-dihydro-2H-[1,2,4]-triazino-[2,3-c]quinazolin-2-one (1.3) and 6-(methoxyphenyl)-8-methyl-3-phenyl-6,7-dihydro-2H-[1,2,4]-triazino-[2,3-c]-quinazolin-2-one (1.4) reveals high non-selective anticancer activity (mean growth -10.53 and 46.24% correspondingly) against 60 cancer cell lines. Substantial dose-depended iv vitro study on 60 cancer cell lines for compound 1.3 showed, that it effectively inhibits growth of SR (lg GI50 = -6,17) of leukemia, NCI-H460 (lg GI50 = -5,79) of non-small lung cancer, HCT-116 (lg GI50 = -5,80), HCT-15 (lg GI50 = -5,78) of colon cancer, SNB-75 (lg GI50 = -5,88), U-251 (lg GI50 = -5,81) of CNS cancer, UACC-257 (lg GI50 = -5,83), UACC-62 (lg GI50 = -5,81) of melanoma, A498 (lg GI50 = -5,80), UO-31 (lg GI50 = -5,81) of renal cancer and MDA-MB-231/ATCC (lg GI50 = -5,81), MDA-MB-468 (lg GI50 = -5,80) of breast cancer cell lines. “Structure-biological activity” relationships for described compounds were discussed.

Author Biography

O. Yu. Voskoboynik, Zaporizhzhia State Medical University

завідувач кафедри органічної і біоорганічної хімії


Kidwai M. Chemotherapy and heterocyclic compounds / M. Kidwai, R. Venkataramanan, R. Mohan, P. Sapra// Curr. Med. Chem. -2002. - №9. – p. 1209-1228.

Denny W. A., The 4-anilinoquinazoline class of inhibitors of the erbB famyli of receptors tyrosine kinases/ W. A. Denny // IL Farmaco. – 2001. - №56. – p. 51-56

. 3. http://dtp.nci.nih.gov/docs/compare/compare.html.

Barker, A.J. PCT Int. Appl. WO 9633979 / Barker, A.J.// Chem. Abstr.- 1997, №126(3).

Cockerill, G.S. PCT Int. Appl. WO 9703069 / Cockerill G.S., Carter M.C.; Mckeown S.K., Vile S., Page M.J., Hudson A.T., Barraclough P., Franzmann K.W. // Chem. Abstr.,- 1997. - №126(15).-199580n.

Spirkova K. Synthesis and biological activity of some 2-substituted quinazolin-4-ones Chem. Pap./ K. Spirkova; S. Stankovsky; A. Mrvova; L. Cipak//1999. - 53(4). – p. 272-275

Thomas A.P. PCT Int. Appl. WO 97 32,856, A.P. Thomas; L.F.A Hennequin.; C. John-stone Chem. Abstr., 1997, 127(20), 278209x.

Кривошей О.В. Синтез, фізико-хімічні властивості та протиракова активність амідів (3-оксо-3,4-дигідро-2Н-[1,2,4]триазино[4,3-c]хіназолін-4-іл)оцтової кислоти / О.В.Кривошей, С.І. Коваленко // Медична хімія. - 2008. – Т.10, №4. – С.109-117.

Воскобойнік О.Ю. Cинтез, перетворення, фізико-хімічні та біологічні властивості [{2-R-(3Н)-хіназолін-4-іліден}гідразоно]карбонових кислот: автореф. дис. на здобуття наук. ступеня канд. фарм. наук : спец. 15.00.02 «Фармацевтична хімія та фармакогнозія»/ О.Ю. Воскобойнік //. - Львів, 2008. - 23 с.

Берест Г.Г. 3-R-6-тіо-6,7-дигідро-2Н-[1,2,4]триазино[2,3-с]хіназолін-2-они: синтез, функціоналізація, фізико-хімічні та біологічні властивості: автореф. дис. на здобуття наук. ступеня канд. фарм. наук : спец. 15.00.02 «Фармацевтична хімія та фармакогнозія»/ Г.Г. Берест  Львів, 2012.  23 с.

Berest G.G. Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides / G.G. Berest, A.Yu. Voskoboynik, S.I. Kovalenko, A.M. Antypenko, I.S. Nosulenko, A. M. Katsev, A.S. Shan-drovskaya // European Journal of Medicinal Chemistry. – 2011. – Vol. 46, Issue 12. - P. 6066-6074.

Berest G.G. Synthesis of new 6-{[-(dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones and evaluation of their anticancer and antimicrobial activities / G.G. Berest, O.Yu. Voskoboynik, S.I. Kovalenko, I.S. Nosulenko, L.M. Antypenko, O.M. Antypenko, V.M. Shvets, A.M. Katsev // Sci. Pharm. – 2012. – Vol. 80, Issue 1. – Р. 37-65.

Kovalenko S.I. N-R-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides with thiazole and thiadiazole fragments in a molecules. Synthesis, phys-ico-chemical properties, cytotoxicity research by bioluminescence inhibition, anticancer activity / S.I. Kovalenko, I.S. Nosulenko, A.Yu. Voskoboynik, G.G. Berest, L.M. An-typenko, A.N. Antipenko, A. M. Katsev // Sci. Pharm. – 2012. – Vol. 80. – P. 837–865.

Kovalenko S. I. Novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]-acetamides: synthesis, cytotoxicity, anticancer activity, compare analysis and docking. / S. I. Kovalenko, I. S. Nosulenko, A. Yu. Voskoboynik [at al.]// Medicinal Chemistry Research. - 2013, V. 22, Issue 6. – P. 2610-2632.



Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines / A. Monks, D. Scudiero, P. Skehan, R. Shoemaker [at al.] // J. Nat. Cancer Inst. – 1991. - №83(11).- p. 757–766.

M.R. Boyd Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen /M.R. Boyd, K.D. Paull // Drug Dev. Res. – 1995. - №34. – p. 91–109.

M.R. Boyd, The NCI In Vitro Anticancer Drug Discovery Screen; Concept, Implementa-tion and Operation, Teicher B.A. (Ed.), Cancer Drug Discovery and Development, vol. 2, Humana Press, 1997, pp. 23–43.

Shoemaker R.H. Application of high-throughput, molecular-targeted screening to anti-cancer drug discovery / R.H. Shoemaker, D. A. Scudiero, G. Melillo // Curr. Top. Med. Chem. – 2002. - №2(3).- p. 229-246.






Pharmaceutical chemistry and pharmacognosy